Siemens Healthineers stock tumbles as spin-off plans shake investor trust

Siemens Healthineers has experienced a tumultuous period in the stock market, with its share price plummeting since late 2023. The company, a pioneer in medical technology, is also forging ahead with new research collaborations while its parent company, Siemens AG, plans to reduce its ownership stake.

The latest developments include a strategic alliance in cardiovascular research and a planned 30% spin-off that has already shaken investor confidence.

In November 2023, Siemens AG announced intentions to spin off 30% of its stake in Siemens Healthineers. Since then, the company's market value has taken a significant hit. The stock reached a one-year high of €58.48 before the announcement but dropped to €40.10 by February 2026—a steep decline.

Currently, the shares are trading at €44.69, slightly above yesterday's close and near the 50-day moving average of €44.31. Despite a minor recovery, the price remains 22.65% below its 52-week peak of €57.78. Over the past month, the stock has risen by 5.90%, though it is still down 12.48% since the start of the year and 14.42% over the last 12 months.

On the research front, Siemens Healthineers recently inked a partnership with Sri Sathya Sai Institute of Higher Medical Sciences. The collaboration focuses on enhancing early detection of cardiovascular diseases through AI-powered echocardiography, expanded imaging, and more precise diagnostics.

Analysts still see potential, with an average target price of €55.47—well above the current trading level. However, the planned spin-off could increase share supply, potentially weighing on demand in the coming months.

The company's stock performance mirrors both market reactions to the spin-off announcement and broader investor sentiment. While recent gains hint at some recovery, the long-term impact of Siemens AG's reduced stake remains uncertain.

The new cardiovascular research initiative underscores Siemens Healthineers' ongoing efforts to bolster its position in medical diagnostics. Analysts continue to project upside, though the stock's trajectory will depend on execution and market conditions.